{
    "clinical_study": {
        "@rank": "28332", 
        "arm_group": [
            {
                "arm_group_label": "mesylate imatinib capsule", 
                "arm_group_type": "Experimental", 
                "description": "Single and multiple oral mesylate imatinib capsule  400mg qd"
            }, 
            {
                "arm_group_label": "Glivec", 
                "arm_group_type": "Active Comparator", 
                "description": "Single and multiple oral Glivec  400mg qd"
            }
        ], 
        "brief_summary": {
            "textblock": "1. purpose: To conduct the relative bioavailability study of a single dose and multiple\n           doses of imatinib mesylate capsule (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus\n           Glivec (Novartis Pharma Stein AG).\n\n        2. Experimental Design\uff1a Two-period crossover design\n\n        3. Test drug: imatinib mesylate capsule Reference drug: Glivec\n\n        4. Sample size\uff1a20"
        }, 
        "brief_title": "Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "detailed_description": {
            "textblock": "To conduct the relative bioavailability study of a single dose and multiple doses of\n      imatinib mesylate capsule(Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus Glivec\n      (Novartis Pharma Stein AG) and compare the bioequivalence and pharmacokinetics of the two\n      products in 20 patients with chronic myeloid leukemia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with chronic myeloid leukemia;\n\n          -  Age: 18-65 years,gender:both.\n\n          -  Weight: standard weight \u00b1 20% within, and avoid weight disparity is too large;\n\n          -  No previous radiation therapy, chemotherapy, or surgery within 1 weeks before\n             treatment with imatinib;\n\n          -  Performance status 0 to 3 (WHO scale); Life expectancy greater than 3 months;\n\n          -  No other malignancy;\n\n          -  Adequate hepatic, renal, and bone marrow function\n             (WBC\u22653.0\u00d7109/L\uff0cANC\u22651.5\u00d7109/L\uff0cPLT\u226580\u00d7109/L. Serum bilirubin\u22641.5\u00d7the institutional\n             upper limit of normal, ALT\u3001ALP\u22642.5\u00d7the institutional upper limit of normal,\n             creatinine\u22641.5\u00d7the institutional upper limit of normal);\n\n          -  Ability to understand objectives of the study, the study procedure, the\n             pharmacological properties of the drug and possible adverse reactions and the\n             willingness to sign a written informed consent.\n\n        Exclusion Criteria:\n\n          -  Suffering from heart, liver, kidney disease or severe acute and chronic\n             gastrointestinal diseases;\n\n          -  Pregnant or lactating women and be sensitive to drug;\n\n          -  Subjects are thought unsuitable for the study by investigators;\n\n          -  Inability to comply with protocol or study procedures in the opinion of the\n             investigator;\n\n          -  Attending other clinical trials or attended other clinical trials 3 months ago."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795716", 
            "org_study_id": "YMTN-1.0"
        }, 
        "intervention": [
            {
                "arm_group_label": "mesylate imatinib capsule", 
                "description": "Single and multiple oral mesylate imatinib capsule   400mg qd", 
                "intervention_name": "mesylate imatinib capsule", 
                "intervention_type": "Drug", 
                "other_name": "111201"
            }, 
            {
                "arm_group_label": "Glivec", 
                "description": "Single and multiple oral Glivec  400mg qd", 
                "intervention_name": "Glivec", 
                "intervention_type": "Drug", 
                "other_name": "Mesylate Imatinib tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2013", 
        "location": {
            "contact": {
                "email": "lizhou999_999@yahoo.com", 
                "last_name": "Zhou Li, doctor", 
                "phone": "13816510379"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200025"
                }, 
                "name": "Shanghai Jiaotong University School of Medicine Ruijin Hospital"
            }, 
            "investigator": {
                "last_name": "Li zhou, doctor", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body", 
        "overall_contact": {
            "email": "lizhou999_999@yahoo.com", 
            "last_name": "Zhou Li, doctor", 
            "phone": "13816510379"
        }, 
        "overall_official": {
            "affiliation": "Shanghai Jiaotong University School of Medicine Ruijin Hospital", 
            "last_name": "Shen Zh xiang, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area Under Curve (AUC) Time Frame: predose, 0.5,1,1.5,2,3,5,8,12,24,48,72hours post-dose", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795716"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}